BioAge says early data suggest ‘best-in-class’ potential for inflammation drug
Summary
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of hea...
Description
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of hea...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source